[Nasopharyngeal carcinoma. Recent data]
- PMID: 15620610
- DOI: 10.1016/j.patbio.2004.01.006
[Nasopharyngeal carcinoma. Recent data]
Abstract
Nasopharyngeal carcinoma (NPC) represents an interesting model in the field of head and neck cancers. This cancer is rare in occidental countries (<1/100,000) and relatively moderate to highly frequent in the Mediterranean area and south-east Asia. This disease is linked to Epstein-Barr virus with a latent infection starting in the oropharyngeal epithelium and involving not only both epithelial tumor cells but also B lymphocytes. This viral infection represents the early phase of carcinogenesis where Latent Membrane Protein-1 has an important role via the terminal part of the BARF-1 gene. There are also various chromosomal alterations reported in NPC concerning the regions of chromosomes 3p, 9p, 11q, 13q, 14q et 16q detected essentially in areas of suppressors genes. Allelic and antigenic specificities of class II and II HLA seems to be associated to an increased risk of NPC different according to the incidence areas. Anti-EBV serology is suggestive of for NPC with an elevated level of IgA EA (early antigen) and VCA (viral capsid antigen). Cyfra 21 represents a promising serum marker for NPC with a 80% sensitivity. Radiotherapy remains the base of loco-regional treatment with a more frequent and systematic use of systemic chemotherapy (primary or concomitant) for high-risk-patients (T3-4 and N2-3 disease).
Similar articles
-
Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.Anticancer Res. 2001 Jul-Aug;21(4B):3021-9. Anticancer Res. 2001. PMID: 11712805
-
Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.Chin Med J (Engl). 2009 May 20;122(10):1173-8. Chin Med J (Engl). 2009. PMID: 19493466
-
Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.Oral Oncol. 2008 Aug;44(8):784-92. doi: 10.1016/j.oraloncology.2007.10.003. Epub 2008 Feb 21. Oral Oncol. 2008. PMID: 18206420
-
[Molecular genetic progression on nasopharyngeal carcinoma].Ai Zheng. 2002 Jan;21(1):1-10. Ai Zheng. 2002. PMID: 12500388 Review. Chinese.
-
Mechanisms of cell immortalization mediated by EB viral activation of telomerase in nasopharyngeal carcinoma.Cell Res. 2006 Oct;16(10):809-17. doi: 10.1038/sj.cr.7310098. Cell Res. 2006. PMID: 17016469 Review.
Cited by
-
Polymorphism analysis of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies from Tunisian patients.Virus Genes. 2007 Apr;34(2):137-45. doi: 10.1007/s11262-006-0051-2. Epub 2007 Jan 11. Virus Genes. 2007. PMID: 17216568
-
[Therapeutic outcomes of nasopharyngeal carcinomas: a single-center study conducted at the Fattouma Bourguiba University Hospital in Monastir, Tunisia].Pan Afr Med J. 2021 Feb 9;38:143. doi: 10.11604/pamj.2021.38.143.15510. eCollection 2021. Pan Afr Med J. 2021. PMID: 33912313 Free PMC article. French.
-
HLA association with nasopharyngeal carcinoma in southern Tunisia.Mol Biol Rep. 2010 Jun;37(5):2533-9. doi: 10.1007/s11033-009-9769-y. Epub 2009 Aug 28. Mol Biol Rep. 2010. PMID: 19714482
-
Nasopharyngeal carcinoma in a south European population: epidemiological data and clinical aspects in Portugal.Eur Arch Otorhinolaryngol. 2010 Oct;267(10):1607-12. doi: 10.1007/s00405-010-1258-3. Epub 2010 May 8. Eur Arch Otorhinolaryngol. 2010. PMID: 20454799
-
[Metastatic nasopharynx cancer at diagnosis: clinical and prognostic (study of 51 cases)].Pan Afr Med J. 2018 Mar 15;29:155. doi: 10.11604/pamj.2018.29.155.11257. eCollection 2018. Pan Afr Med J. 2018. PMID: 30050619 Free PMC article. French.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
